These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16968355)

  • 1. Mortality in a cohort of opiate and amphetamine users in Perth, Western australia: Comment on Bartu et al. (2006).
    Stoové M
    Addiction; 2006 Oct; 101(10):1523-4; author reply 1524. PubMed ID: 16968355
    [No Abstract]   [Full Text] [Related]  

  • 2. Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia.
    Bartu A; Freeman NC; Gawthorne GS; Codde JP; Holman CD
    Addiction; 2004 Jan; 99(1):53-60. PubMed ID: 14678062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients.
    Soyka M; Apelt SM; Lieb M; Wittchen HU
    J Clin Psychopharmacol; 2006 Dec; 26(6):657-60. PubMed ID: 17110826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study.
    Clausen T; Anchersen K; Waal H
    Drug Alcohol Depend; 2008 Apr; 94(1-3):151-7. PubMed ID: 18155364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opiate substitution and death. GPs need guidance, please.
    Wilson P
    BMJ; 2010 Nov; 341():c6515. PubMed ID: 21098592
    [No Abstract]   [Full Text] [Related]  

  • 6. Problem drug users.
    Byrne A
    Br J Gen Pract; 1996 Mar; 46(404):200. PubMed ID: 8731633
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation.
    Ngo HT; Tait RJ; Hulse GK
    Arch Gen Psychiatry; 2008 Apr; 65(4):457-65. PubMed ID: 18391134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program.
    Raffa JD; Grebely J; Tossonian H; Wong T; Viljoen M; Khara M; Mead A; McLean M; Duncan F; Petkau AJ; DeVlaming S; Conway B
    Drug Alcohol Depend; 2007 Jul; 89(2-3):306-9. PubMed ID: 17383117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users.
    Banta-Green CJ; Maynard C; Koepsell TD; Wells EA; Donovan DM
    Addiction; 2009 May; 104(5):775-83. PubMed ID: 19344438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment.
    Tait RJ; Ngo HT; Hulse GK
    J Subst Abuse Treat; 2008 Sep; 35(2):116-24. PubMed ID: 17931824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.
    Degenhardt L; Randall D; Hall W; Law M; Butler T; Burns L
    Drug Alcohol Depend; 2009 Nov; 105(1-2):9-15. PubMed ID: 19608355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: A randomized controlled trial.
    Robertson JR; Raab GM; Bruce M; McKenzie JS; Storkey HR; Salter A
    Addiction; 2006 Dec; 101(12):1752-9. PubMed ID: 17156174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure to opioid maintenance treatment reduces long-term mortality.
    Gibson A; Degenhardt L; Mattick RP; Ali R; White J; O'Brien S
    Addiction; 2008 Mar; 103(3):462-8. PubMed ID: 18190664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment.
    Stenbacka M; Beck O; Leifman A; Romelsjö A; Helander A
    Drug Alcohol Rev; 2007 Jan; 26(1):55-63. PubMed ID: 17364837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal overdoses and deaths by other causes in a cohort of Norwegian drug abusers--a competing risk approach.
    Ødegård E; Amundsen EJ; Kielland KB
    Drug Alcohol Depend; 2007 Jul; 89(2-3):176-82. PubMed ID: 17240086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of methadone maintenance treatment utilization in a multisite cohort of illicit opioid users (OPICAN).
    Fischer B; Cruz MF; Patra J; Rehm J
    J Subst Abuse Treat; 2008 Apr; 34(3):340-6. PubMed ID: 17614236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing cancer mortality among opioid-dependent persons in Australia: a new public health challenge for a disadvantaged population.
    Randall D; Degenhardt L; Vajdic CM; Burns L; Hall WD; Law M; Butler T
    Aust N Z J Public Health; 2011 Jun; 35(3):220-5. PubMed ID: 21627721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methadone and the QT interval: relations to the serum concentrations of methadone and its enantiomers (R)-methadone and (S)-methadone.
    Skjervold B; Bathen J; Spigset O
    J Clin Psychopharmacol; 2006 Dec; 26(6):687-9. PubMed ID: 17110841
    [No Abstract]   [Full Text] [Related]  

  • 19. [Opiate replacement therapy in France: assessment of the public policies].
    Chast F
    Ann Pharm Fr; 2009 Sep; 67(5):299-303. PubMed ID: 19695365
    [No Abstract]   [Full Text] [Related]  

  • 20. Women on methadone.
    Sherman J
    Aust Fam Physician; 2006 Nov; 35(11):839; author reply 839. PubMed ID: 17120337
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.